Perspective Therapeutics (NYSE:CATX) Price Target Lowered to $15.00 at Royal Bank of Canada

Perspective Therapeutics (NYSE:CATX) had its target price decreased by Royal Bank of Canada from $16.00 to $15.00 in a report issued on Thursday,Benzinga reports. Royal Bank of Canada currently has an outperform rating on the stock.

Several other analysts also recently issued reports on CATX. Wedbush reiterated an “outperform” rating and issued a $11.00 price target on shares of Perspective Therapeutics in a report on Wednesday. Cantor Fitzgerald upgraded Perspective Therapeutics to a “strong-buy” rating in a research note on Tuesday, March 4th. Lifesci Capital upgraded Perspective Therapeutics to a “strong-buy” rating in a report on Thursday, March 6th. Brookline Capital Management upgraded shares of Perspective Therapeutics to a “strong-buy” rating in a research note on Monday, March 10th. Finally, Scotiabank began coverage on shares of Perspective Therapeutics in a research note on Friday, March 7th. They issued a “sector outperform” rating and a $15.00 target price for the company. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat, Perspective Therapeutics currently has an average rating of “Buy” and an average target price of $14.44.

Perspective Therapeutics Trading Up 1.3 %

CATX opened at $2.30 on Thursday. Perspective Therapeutics has a 52-week low of $2.22 and a 52-week high of $19.05. The company has a 50 day moving average of $2.96 and a two-hundred day moving average of $6.51.

Institutional Trading of Perspective Therapeutics

Several institutional investors have recently added to or reduced their stakes in CATX. Y Intercept Hong Kong Ltd bought a new stake in shares of Perspective Therapeutics in the 4th quarter worth about $33,000. Aigen Investment Management LP bought a new stake in Perspective Therapeutics in the fourth quarter valued at about $34,000. National Bank of Canada FI raised its stake in Perspective Therapeutics by 549,900.0% during the fourth quarter. National Bank of Canada FI now owns 11,000 shares of the company’s stock valued at $35,000 after buying an additional 10,998 shares in the last quarter. ProShare Advisors LLC lifted its holdings in Perspective Therapeutics by 49.1% during the 4th quarter. ProShare Advisors LLC now owns 15,225 shares of the company’s stock worth $49,000 after buying an additional 5,011 shares during the last quarter. Finally, Vontobel Holding Ltd. acquired a new position in shares of Perspective Therapeutics in the 4th quarter worth approximately $51,000. 54.66% of the stock is owned by institutional investors and hedge funds.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.